Human clinical trials could begin as early as next year
A team of researchers at the University of Georgia’s Regenerative Bioscience Center and ArunA Biomedical, a UGA startup company, have developed a new treatment for stroke that reduces brain damage and accelerates the brain’s natural healing tendencies in animal models. They published their findings in the journal Translational Stroke Research.
The research team led by UGA professor Steven Stice and Nasrul Hoda of Augusta University created a treatment called AB126 using extracellular vesicles (EV), fluid-filled structures known as exosomes, which are generated from human neural stem cells.
Fully able to cloak itself within the bloodstream, this type of regenerative EV therapy appears to be the most promising in overcoming the limitations of many cell therapies—with the ability for exosomes to carry and deliver multiple doses—as well as the ability to store and administer treatment. Small in size, the tiny tubular shape of an exosome allows EV therapy to cross barriers that cells cannot.
“This is truly exciting evidence, because exosomes provide a stealth-like characteristic, invisible even to the body’s own defenses,” said Stice, Georgia Research Alliance Eminent Scholar and D.W. Brooks Distinguished Professor in the College of Agricultural and Environmental Sciences. “When packaged with therapeutics, these treatments can actually change cell progression and improve functional recovery.”
Following the administration of AB126, the researchers used MRI scans to measure brain atrophy rates in preclinical, age-matched stroke models, which showed an approximately 35 percent decrease in the size of injury and 50 percent reduction in brain tissue loss—something not observed acutely in previous studies of exosome treatment for stroke.
Outside of rodents, the results were replicated by Franklin West, associate professor of animal and dairy science, and fellow RBC members using a porcine model of stroke—the only one of its kind in the U.S.
Based on these pre-clinical results, ArunA Biomedical plans to begin human studies in 2019, said Stice, who is also chief scientific officer of ArunA Biomedical.
“Until now, we had very little evidence specific to neural exosome treatment and the ability to improve motor function,” said Stice. “Just days after stroke, we saw better mobility, improved balance and measurable behavioral benefits in treated animal models.”
Named as part of the ‘stroke belt’ region, Georgia continues to exceed the national average in stroke deaths, which is the third leading cause of death in the U.S., with more than 140,000 Americans dying each year, according to the Centers for Disease Control and Prevention.
ArunA recently unveiled advances to the company’s proprietary neural cell platform for the production of exosome manufacturing. Today, ArunA’s manufacturing process positions the company to produce AB126 exosomes at a scale to meet early clinical demand. The company has plans to expand this initiative beyond stroke for preclinical studies in epilepsy, traumatic brain and spinal cord injuries later this year.
The Latest on: Stroke treatment
- Type 2 diabetes: Symptoms, treatment and difference from type 1 for World Diabetes Day 2018 on November 14, 2018 at 7:00 am
Studies suggest that type 2 diabetes greatly increases the risk of heart attack or stroke. This is because people with type ... so speak to your GP who can advise you on what treatment is right for yo... […]
- Power up! Sunset Park hospital’s new video game helps stroke victims recover on November 14, 2018 at 12:53 am
This treatment is next level! A Sunset Park medical center is using new video-game technology to help stroke survivors and victims of other brain injuries regain motor function, a treatment one hospit... […]
- New treatment, combined with statins, could largely reduce heart attacks and strokes on November 13, 2018 at 5:06 pm
stroke or other ischemic events. In a new study, researchers at Baylor College of Medicine have shown that a particular treatment strongly reduced cardiovascular events, including cardiovascular ... […]
- Developer of urine-linked drug files to raise $15M through public offering on November 12, 2018 at 9:51 am
DM199 is a synthetic version of a protein called KLK1. Versions of KLK1 derived from human urine are sold in markets such as China and Korea for the treatment of stroke and other conditions, including ... […]
- How new technology is improving treatment of strokes on November 12, 2018 at 9:37 am
For patients experiencing ischemic stroke — the leading cause of disability in the U.S., according to the Centers for Disease Control and Prevention — the time it takes to receive treatment is critica... […]
- Study: How vitamin D and fish oil affect risk of heart attack, stroke and cancer on November 12, 2018 at 7:12 am
After a median of five years of treatment, 805 participants had suffered a major adverse cardiovascular event, such as a heart attack or stroke (386 in the omega-3 group and 419 in the placebo group). […]
- Bathurst Hospital stroke treatment benefits patients on November 8, 2018 at 9:41 pm
NEW software installed on CT scanners at Bathurst Base Hospital is helping boost the recovery chances of local people who have suffered a stroke. The software allows stroke radiology teams to accurate... […]
- Cancer drug points to stroke treatment for young people: Aussie-led research on November 7, 2018 at 5:25 pm
SYDNEY, Nov. 8 (Xinhua) -- A drug used to treat cancer patients could also be a treatment option for a leading cause of stroke in young people, according to latest Australian-led research. Researchers ... […]
- Stroke sufferers in rural areas wait three hours for treatment on November 5, 2018 at 9:36 pm
People who suffer stroke in rural areas are taking more than three hours to reach hospital, a new report has warned. It calls for a need to re-activate public awareness campaigns about the symptoms of ... […]
- North Oaks Medical Center using stroke treatment with wider time limits on November 2, 2018 at 1:32 pm
HAMMOND — The treatment window for the most common type of stroke has expanded from three hours to 24 hours at North Oaks Medical Center because of enhanced interventional radiology capabilities made ... […]
via Google News and Bing News